Boron Containing Doai Patents (Class 514/64)
-
Patent number: 10352931Abstract: The present invention provides a diagnostic device allowing highly specific and efficient in vivo and/or in vitro detection of a bio marker in a broad range of bodily fluids or tissues. The diagnostic device is composed of a binding agent that specifically binds a bio marker present in the bodily fluid linked by a linker compound or layer to the substrate, which includes a metallic, a semiconductor, or a polymeric carrier. The present invention further provides methods using said device for the detection of bio markers, as well as kits comprising said device and suitable ingredients for the detections of bio markers in a bodily fluid. Furthermore, the invention provides suitable in vivo and in vitro applications of said binding agent for the detection of specific disease-related target structures.Type: GrantFiled: August 27, 2014Date of Patent: July 16, 2019Assignee: GILUPI GMBHInventor: Björn Nowack
-
Patent number: 10314795Abstract: The present invention includes compounds useful in preventing, treating or ameliorating Sigma-related disorders or diseases. The compounds of the invention may modulate cellular protein homeostasis, which includes: translation initiation, folding, processing, transport, and degradation (including ubiquitin selective autophagy) of proteins. The present invention also includes methods of preventing, treating or ameliorating a Sigma-related disorder or disease in a subject in need thereof, the method comprising administering to the subject an effective amount of a Sigma-modulating compound. The present invention also includes methods of preventing, treating or ameliorating a Sigma-related disorder or disease in a subject in need thereof, the method comprising administering to the subject an effective amount of a Sigma-modulating compound, further comprising administering an effective amount of a compound that inhibits the ubiquitin proteasome system (UPS) and/or autophagic survival pathways.Type: GrantFiled: September 22, 2017Date of Patent: June 11, 2019Assignee: Drexel UniversityInventors: Felix J. Kim, Joseph M. Salvino
-
Patent number: 10314308Abstract: Compounds of formula (I) are as defined in the claims, and their use in compositions and methods for the control and/or prevention of microbial infection, particularly fungal infection, in plants and to processes for the preparation of these compounds.Type: GrantFiled: January 13, 2016Date of Patent: June 11, 2019Assignee: SYNGENTA PARTICIPATIONS AGInventors: Ramya Rajan, Daniel Stierli, Renaud Beaudegnies, Peter Renold
-
Patent number: 10294246Abstract: Compounds of formula (I) are inhibitors of LMP7 and can be employed, inter alia, for the treatment of an autoimmune disorder or hematological malignancies.Type: GrantFiled: October 1, 2015Date of Patent: May 21, 2019Assignee: MERCK PATENT GMBHInventors: Markus Klein, Oliver Schadt, Philipp Haselmayer, Michael Busch
-
Patent number: 10292976Abstract: The present invention aims to prevent and/or treat malaria using an antimalarial drug comprising, as an active ingredient, a metal chelator represented by the following formula (I), (III), (IV), (V), (VI), or (VII), such as tris(2-pyridylmethyl)amine.Type: GrantFiled: October 23, 2018Date of Patent: May 21, 2019Assignee: RIKENInventors: Akira Wada, Hiroki Hayase, Nobumoto Watanabe, Hiroyuki Osada, Takeshi Shimizu, Konstanty Wierzba
-
Patent number: 10293048Abstract: A pharmaceutical composition and preparing processes thereof. The composition comprises bortezomib or pharmaceutically acceptable salt or solvate thereof, tromethamine and an organic carboxylic acid, and the pH of the composition is from about 3.0 to 6.0.Type: GrantFiled: March 1, 2013Date of Patent: May 21, 2019Assignee: DR. REDDY'S LABORATORIES LIMITEDInventors: Navin Vaya, Harshal Prabhakar Bhagwatwar, Rakeshwar Bandichhor, Nirmal Khati, Riyaz Ahmed Shaik, Rahul Bhise, Yakaswamy Asalla, Rajkumar Bhimrao Shinde
-
Patent number: 10214547Abstract: Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.Type: GrantFiled: October 18, 2017Date of Patent: February 26, 2019Assignee: VENATORX PHARMACEUTICALS, INC.Inventors: Christopher J. Burns, Denis Daigle, Bin Liu, Daniel McGarry, Daniel C. Pevear, Robert E. Lee Trout
-
Patent number: 10183908Abstract: The present invention relates to novel compounds and their use in the prophylactic and/or therapeutic treatment of kidney and/or liver disease.Type: GrantFiled: March 18, 2016Date of Patent: January 22, 2019Assignee: VECTUS BIOSYSTEMS LIMITEDInventor: Karen Annette Duggan
-
Patent number: 10125152Abstract: Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.Type: GrantFiled: August 11, 2017Date of Patent: November 13, 2018Assignee: VENATORX PHARMACEUTICALS, INC.Inventors: Christopher J. Burns, Denis Daigle, Bin Liu, Daniel McGarry, Daniel C. Pevear, Robert E. Lee Trout, Randy W. Jackson
-
Patent number: 10117944Abstract: The present invention provides pharmacological compounds including an effector moiety conjugated to a binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds. The compounds can be described as a protein interacting binding moiety-drug conjugate (SDC-TRAP) compounds, which include a protein interacting binding moiety and an effector moiety. For example, in certain embodiments directed to treating cancer, the SDC-TRAP can include an Hsp90 inhibitor conjugated to a cytotoxic agent as the effector moiety.Type: GrantFiled: July 28, 2016Date of Patent: November 6, 2018Assignee: MADRIGAL PHARMACEUTICALS, INC.Inventors: Dinesh U. Chimmanamada, Weiwen Ying
-
Patent number: 10118936Abstract: The present invention is directed to arginase inhibitor compounds of formula IA or formula IB: or a pharmaceutically acceptable salt thereof, compositions containing these compounds, and methods of their use for the treatment and diagnosis of conditions characterized by upregulation of arginase, abnormally high arginase activity, or by abnormally low nitric oxide synthase activity.Type: GrantFiled: December 4, 2015Date of Patent: November 6, 2018Assignees: The Trustees of the University of Pennsylvania, AstraZeneca ABInventors: David W. Christianson, Bruce Edward Tomczuk, Richard Scott Pottorf, Andrew Vargha Colasanti, Gary Lee Olson
-
Patent number: 10093685Abstract: Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.Type: GrantFiled: August 11, 2017Date of Patent: October 9, 2018Assignee: VENATORX PHARMACEUTICALS, INC.Inventors: Christopher J. Burns, Denis Daigle, Bin Liu, Daniel McGarry, Daniel C. Pevear, Robert E. Lee Trout, Randy W. Jackson
-
Patent number: 10085452Abstract: An anti-fungal composition for the control of one or more target fungi (or a similar heterotrophic, hyphae-producing organism) that infect plant materials and are(is) separately controllable by a benzoxaborole and an anti-fungal compound of a preselected FRAC Target Site Code is disclosed, as is a method of its use. A composition contains a diluent medium having dissolved or dispersed therein a synergistic effective amount of each of a first and a second anti-fungal compound. The first anti-fungal compound is a benzoxaborole of Formula I. The second anti-fungal compound is other than a benzoxaborole and is known to control said one or more target species of fungus when utilized as the sole anti-fungal compound at a concentration greater than the synergistic effective amount and has a preselected FRAC Target Site Code of B, C, D, E, G, H, or M.Type: GrantFiled: July 7, 2017Date of Patent: October 2, 2018Assignee: The Penn State Research FoundationInventors: Stephen Benkovic, Chunyu Liu
-
Patent number: 10072029Abstract: The present disclosure relates to a novel crystalline form of a proteasome inhibitor, and to the processes for the preparation thereof. The novel crystalline form according to the disclosure may be used in the preparation of pharmaceutical compositions for the treatment of cancer.Type: GrantFiled: February 10, 2016Date of Patent: September 11, 2018Assignee: Millennium Pharmaceuticals, Inc.Inventors: Marianne Langston, Debra Mazaik, Eric Elliott, Anton Peterson, Patricia Andres, Jing Teng
-
Patent number: 10065974Abstract: The invention relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the invention. Also provided herein are methods of treating cancer with the arginase inhibitors of the invention.Type: GrantFiled: October 28, 2016Date of Patent: September 4, 2018Inventors: Eric B. Sjogren, Jim Li, Michael Van Zandt, Darren Whitehouse
-
Patent number: 10011616Abstract: This invention provides, among other things, novel compounds useful for treating protozoal infections, pharmaceutical compositions containing such compounds, as well as combinations of these compounds with at least one additional therapeutically effective agent.Type: GrantFiled: April 8, 2016Date of Patent: July 3, 2018Assignee: MMV MEDICINES FOR MALARIA VENTUREInventors: Yong-Kang Zhang, Jacob J. Plattner, Robert T. Jacobs
-
Patent number: 10004730Abstract: A method for treating prostate cancer in a subject, comprising administering a therapeutically effective amount of at least one agent to the subject, wherein the agent is selected from: (a) a phenyl-substituted imidazole, or a pharmaceutically acceptable salt or ester thereof; or (b) a compound, or a pharmaceutically acceptable salt or ester thereof, having a formula I of: ?wherein R20 is an aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a silyl-containing group, a boryl-containing group, a phosphine-containing group, amino, a thio-containing group, a seleno-containing group, halide, or a nitro-containing group; R21 is an alkanediyl or a substituted alkanediyl; a is 0 or 1; c is 0 or 1; X is C or S; R22 is a moiety that includes at least one divalent amino radical; and R23 is an aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a silyl-containingType: GrantFiled: March 13, 2017Date of Patent: June 26, 2018Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: Zhou Wang, Joel Byron Nelson, Minh Bao Nguyen, John S. Lazo, Paul A. Johnston, Peter Wipf
-
Patent number: 9949995Abstract: A method of treating a bacterial infection in a subject in need thereof includes administering to the subject therapeutically effective amounts of at least one ?-lactam antibiotic and at least one triazolylmethyl boronic acid.Type: GrantFiled: September 6, 2016Date of Patent: April 24, 2018Assignee: Case Western Reserve UniversityInventors: Robert Bonomo, Fabio Prati, Emilia Caselli, Chiara Romagnoli
-
Patent number: 9944658Abstract: Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.Type: GrantFiled: March 13, 2014Date of Patent: April 17, 2018Assignee: VENATORX PHARMACEUTICALS, INC.Inventors: Christopher J. Burns, Denis Daigle, Bin Liu, Daniel McGarry, Daniel C. Pevear, Robert E. Lee Trout
-
Patent number: 9944660Abstract: The present invention provides a tricyclic compound represented by general formula (I), a pharmaceutical salt thereof, or a stereoisomer thereof exhibits excellent antibacterial activity against Gram-negative bacteria resistant bacteria thereof, and also being excellent in terms of safety. Furthermore, the present invention provides production processes, pharmaceutical compositions comprising a tricyclic compound, a pharmaceutically acceptable salt thereof, or a stereoisomer thereof as an active ingredient and use thereof as a pharmaceutical agent. The compounds of the present invention are useful for the treatment and/or prevention of disease such as complicated urinary tract infections (cUTIs), nosocomial pneumonia, intra-abdominal infections (IAIs) or bacteremia.Type: GrantFiled: December 29, 2016Date of Patent: April 17, 2018Assignee: Daiichi Sankyo Company, LimitedInventors: Ajay Soni, Aditi Agarwal, Sangram Shesharao Deshmukh, Kedar Padmakar Purnapatre, Shinji Marumoto
-
Patent number: 9937154Abstract: The described invention relates to methods for preventing or treating graft-versus-host disease while preserving a graft-versus-tumor effect, increasing survival of, preserving alloreactivity, or a combination thereof in a patient with a tumor receiving a transplant. The described methods comprise administering to the patient a therapeutic amount of a pharmaceutical composition comprising a Rho kinase inhibitor compound, e.g., telmisartan or related angiotensin receptor blockers, and a pharmaceutically acceptable excipient. The therapeutic amount may be effective to attenuate graft-versus-host disease and to preserve the graft-versus-tumor effect of the transplant.Type: GrantFiled: June 3, 2016Date of Patent: April 10, 2018Assignee: Hackensak University Medical CenterInventors: David Schwartz, Sujatha Iyengar
-
Patent number: 9889146Abstract: Norvaline and/or other amino acids that are capable of being acylated onto tRNALeu by LeuRS, in combination with substituted benzoxaboroles, such as a compound having a structure according to formula III: and methods for decreasing the frequency of resistance and/or reducing the rate of resistance and/or suppressing the emergence of resistance that develops in bacteria exposed to a substituted benzoxaborole or salt thereof by administering a combination of a substituted benzoxaborole such as a compound of formula III or salt thereof and an amino acid or a salt thereof.Type: GrantFiled: May 23, 2016Date of Patent: February 13, 2018Assignee: Anacor Pharmaceuticals, Inc.Inventors: Michael Richard Kevin Alley, Katherine Widdowson
-
Patent number: 9861626Abstract: The present invention aims to prevent and/or treat malaria using an antimalarial drug comprising, as an active ingredient, a metal chelator represented by the following formula (I), (III), (IV), (V), (VI), or (VII), such as tris(2-pyridylmethyl)amine.Type: GrantFiled: January 9, 2015Date of Patent: January 9, 2018Assignee: RIKENInventors: Akira Wada, Hiroki Hayase, Nobumoto Watanabe, Hiroyuki Osada, Takeshi Shimizu, Konstanty Wierzba
-
Patent number: 9828391Abstract: Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.Type: GrantFiled: July 18, 2016Date of Patent: November 28, 2017Assignee: VENATORX PHARMACEUTICALS, INC.Inventors: Christopher J. Burns, Denis Daigle, Bin Liu, Daniel McGarry, Daniel C. Pevear, Robert E. Lee Trout
-
Patent number: 9771382Abstract: Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.Type: GrantFiled: June 27, 2016Date of Patent: September 26, 2017Assignee: VENATORX PHARMACEUTICALS, INC.Inventors: Christopher J. Burns, Denis Daigle, Bin Liu, Daniel McGarry, Daniel C. Pevear, Robert E. Lee Trout, Randy W. Jackson
-
Patent number: 9750758Abstract: The technology described herein relates to pinacolyl boronate substituted stilbenes for the treatment of cancers, e.g. cancers expressing abnormally high levels of SREBP1.Type: GrantFiled: June 10, 2013Date of Patent: September 5, 2017Assignee: Thomas Jefferson UniversityInventors: Chenguang Wang, Jie Zhou
-
Patent number: 9717732Abstract: The invention provides a composition which comprises (a) a PDE3/PDE4 inhibitor which is 9,10-Dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one or a pharmaceutically acceptable acid addition salt thereof and (b) a ?2-adrenergic receptor agonist.Type: GrantFiled: March 17, 2014Date of Patent: August 1, 2017Assignee: VERONA PHARMA PLCInventors: Michael J. A. Walker, Mario Cazzola, Luigino Calzetta
-
Patent number: 9682092Abstract: Methods of treating anti-inflammatory conditions through the use of boron-containing small molecules are disclosed.Type: GrantFiled: April 16, 2015Date of Patent: June 20, 2017Assignee: Anacor Pharmaceuticals, Inc.Inventors: Stephen J. Baker, Virginia Sanders, Tsutomu Akama, Carolyn Bellinger-Kawahara, Yvonne Freund, Kirk R. Maples, Jacob J. Plattner, Yong-Kang Zhang, Huchen Zhou, Vincent S. Hernandez
-
Patent number: 9637504Abstract: Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.Type: GrantFiled: May 23, 2016Date of Patent: May 2, 2017Assignee: VENATORX PHARMACEUTICALS, INC.Inventors: Christopher J. Burns, Denis Daigle, Bin Liu, Randy W. Jackson, Jodie Hamrick, Daniel McGarry, Daniel C. Pevear, Robert E. Lee Trout
-
Patent number: 9630935Abstract: The present invention relates to novel compounds and their use in the prophylactic and/or therapeutic treatment of hypertension and/or fibrosis.Type: GrantFiled: September 17, 2014Date of Patent: April 25, 2017Assignee: VECTUS BIOSYSTEMS LIMITEDInventor: Karen Annette Duggan
-
Patent number: 9617225Abstract: Novel 4,6-disubstituted aminopyrimidine derivatives with the following structure (I) have anti-HIV activity.Type: GrantFiled: August 23, 2013Date of Patent: April 11, 2017Assignee: VIROSTATICS SRLInventors: Franco Lori, James Chafouleas, Davide De Forni, Antonio Solinas, Zoltán Varga, Zoltán Greff, László Örfi, György Kéri
-
Patent number: 9603775Abstract: The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited for storage of pharmaceutical compositions and, specifically, a pharmaceutical solution comprising a pharmaceutically active ingredient, for example, VELCADE (bortezomib), STELARA (Ustekinumab), SIMPONI (golimumab), siltuximab, and AMG 403 (fulranumab).Type: GrantFiled: April 23, 2014Date of Patent: March 28, 2017Assignee: Corning IncorporatedInventors: Wendell P. Weeks, Robert Anthony Schaut, Steven Edward DeMartino, John Stephen Peanasky
-
Patent number: 9598443Abstract: This invention provides, among other things, novel compounds useful for treating protozoal infections, pharmaceutical compositions containing such compounds, as well as combinations of these compounds with at least one additional therapeutically effective agent.Type: GrantFiled: January 31, 2014Date of Patent: March 21, 2017Assignee: Anacor Pharmaceuticals, Inc.Inventors: Tsutomu Akama, Eric Easom, Yvonne Freund, Jacob J. Plattner, Jessica Sligar, Daitao Chen, Jennifer Freeman, Joe Perales
-
Patent number: 9585958Abstract: The present disclosure provides methods of reducing levels of lactate in a fluid or tissue in an individual. The present disclosure provides pharmaceutical compositions suitable for use in the methods.Type: GrantFiled: September 19, 2014Date of Patent: March 7, 2017Inventors: Abhinav P. Acharya, Niren Murthy, Elliot C. Woods
-
Patent number: 9572823Abstract: This invention relates to compounds useful for treating fungal infections, more specifically topical treatment of onychomycosis and/or cutaneous fungal infections. This invention is directed to compounds that are active against fungi and have properties that allow the compound, when placed in contact with a patient, to reach the particular part of the skin, nail, hair, claw or hoof infected by the fungus. In particular the present compounds have physiochemical properties that facilitate penetration of the nail plate.Type: GrantFiled: April 5, 2016Date of Patent: February 21, 2017Assignee: Anacor Pharmaceuticals, Inc.Inventors: Stephen J. Baker, Tsutomu Akama, Vincent S. Hernandez, Karin M. Hold, Kirk Maples, Jacob J. Plattner, Virginia Sanders, Yong-Kang Zhang, Gregory T. Fieldson, James J. Leyden
-
Patent number: 9566290Abstract: This invention relates to compounds useful for treating fungal infections, more specifically topical treatment of onychomycosis and/or cutaneous fungal infections. This invention is directed to compounds that are active against fungi and have properties that allow the compound, when placed in contact with a patient, to reach the particular part of the skin, nail, hair, claw or hoof infected by the fungus. In particular the present compounds have physiochemical properties that facilitate penetration of the nail plate.Type: GrantFiled: April 20, 2016Date of Patent: February 14, 2017Assignee: Anacor Pharmaceuticals, Inc.Inventors: Stephen J. Baker, Tsutomu Akama, Vincent S. Hernandez, Karin M. Hold, Kirk Maples, Jacob J. Plattner, Virginia Sanders, Yong-Kang Zhang, Gregory T. Fieldson, James J. Leyden
-
Patent number: 9566289Abstract: This invention relates to compounds useful for treating fungal infections, more specifically topical treatment of onychomycosis and/or cutaneous fungal infections. This invention is directed to compounds that are active against fungi and have properties that allow the compound, when placed in contact with a patient, to reach the particular part of the skin, nail, hair, claw or hoof infected by the fungus. In particular the present compounds have physiochemical properties that facilitate penetration of the nail plate.Type: GrantFiled: February 17, 2016Date of Patent: February 14, 2017Assignee: Anacor Pharmaceuticals, Inc.Inventors: Stephen J. Baker, Tsutomu Akama, Vincent S. Hernandez, Karin M. Hold, Kirk Maples, Jacob J. Plattner, Virginia Sanders, Yong-Kang Zhang, Gregory T. Fieldson, James J. Leyden
-
Patent number: 9549908Abstract: A composition for inducing differentiation into beige adipocytes from white adipocytes, including butein, a butein derivative, or a pharmaceutically available salt thereof as an active ingredient, and a method of inducing the differentiation are provided. Increases in expressions of UCP-1 and PRDM4 are confirmed using the active ingredient, that is, the butein or butein derivative, and therefore the composition is expected to be used in preventing or treating obesity, and more basically, for target treatment.Type: GrantFiled: June 22, 2015Date of Patent: January 24, 2017Assignees: Research & Business Foundation Sungkyunkwan University, Ltd., Gyeonggi Institute of Science & Technology PromotionInventors: Kye Won Park, Nojoon Song, Suk Chan Lee, Jin-Mo Ku
-
Patent number: 9549938Abstract: This invention relates to compounds useful for treating fungal infections, more specifically topical treatment of onychomycosis and/or cutaneous fungal infections. This invention is directed to compounds that are active against fungi and have properties that allow the compound, when placed in contact with a patient, to reach the particular part of the skin, nail, hair, claw or hoof infected by the fungus. In particular the present compounds have physiochemical properties that facilitate penetration of the nail plate.Type: GrantFiled: March 11, 2016Date of Patent: January 24, 2017Assignee: Anacor Pharmaceuticals, Inc.Inventors: Stephen J. Baker, Tsutomu Akama, Vincent S. Hernandez, Karin M. Hold, Kirk Maples, Jacob J. Plattner, Virginia Sanders, Yong-Kang Zhang, Gregory T. Fieldson, James J. Leyden
-
Patent number: 9469659Abstract: A method of treating a disease comprising administering to a subject a therapeutically effective amount of a compound that includes the structure of general Formula II, pharmaceutically acceptable salts thereof, and/or solvates thereof: wherein R1, R2, R3, are independently selected from the group consisting of null, hydroxy, alkoxy, and halo, or R1 and R2 taken together form a cyclic boronate ester and R3 is null; wherein when four bonds to boron are present, boron bears a formal negative charge and the structure further comprises a countercation that is potassium or sodium, X1, X2, X3, and X4 are independently selected from the group consisting of O, CH, and N, with the proviso that no more than two of combined O and N are selected, and Z is selected from the group consisting of hydrogen, alkyl, aryl, heteroaryl, and halogen, any of which may be optionally substituted. Such compounds can increase glucose uptake by cells and preferably do not substantially increase adipogenesis.Type: GrantFiled: January 7, 2016Date of Patent: October 18, 2016Assignee: BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGEInventors: Nikhil V. Dhurandhar, Bhaskar C. Das
-
Patent number: 9464098Abstract: The invention is concerned with the compounds of formula (I) and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula I are LMP7 inhibitors and may be useful in treating associated inflammatory diseases and disorders such as, for example, rheumatoid arthritis, lupus and irritable bowel disease.Type: GrantFiled: November 29, 2013Date of Patent: October 11, 2016Assignee: HOFFMANN-LA ROCHE INC.Inventors: Stephen M. Lynch, Werner Neidhart, Jean-Marc Plancher, Tanja Schulz-Gasch
-
Patent number: 9426996Abstract: This invention is related to use of a volatile antimicrobial compound against pathogens affecting meats, plants, or plant parts. The volatile antimicrobial compounds provided include certain oxaborole compounds, for example benzoxaboroles. Delivery systems are provided to take advantage of the volatile nature of these antimicrobial compounds. Also combinations with a volatile plant growth regulator, for example 1-methylcyclopropene, are disclosed.Type: GrantFiled: June 2, 2014Date of Patent: August 30, 2016Assignee: AgroFresh Inc.Inventors: Daniel Maclean, David H. Young, Richard M. Jacobson, Maurice C. Yap, Rodrigo A. Cifuentes, Donald H. DeVries, Joseph D. Eckelbarger
-
Patent number: 9429574Abstract: The present invention provides an inhibitor of the ubiquitin-proteasome system for use in treating cancer in a patient, wherein the patient is assessed to establish that the cancer is associated with cells in which the functional activity of SMARCB1 is low or absent. In one embodiment, the patient has, or is suspected of having, breast cancer, an atypical teratoid rhabdoid tumor (AT/RT) and/or a malignant rhabdoid tumor (MRT). In one embodiment, the proteasome inhibitor is Bortezomib. Further aspects of the invention provide related uses and methods.Type: GrantFiled: November 21, 2012Date of Patent: August 30, 2016Inventor: Ulrike Nuber
-
Patent number: 9422314Abstract: Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.Type: GrantFiled: December 5, 2013Date of Patent: August 23, 2016Assignee: VENATORX PHARMACEUTICALS, INC.Inventors: Christopher J. Burns, Denis Daigle, Bin Liu, Daniel McGarry, Daniel C. Pevear, Robert E. Lee Trout
-
Patent number: 9416146Abstract: Compounds and methods of treating anti-inflammatory conditions are disclosed.Type: GrantFiled: March 23, 2015Date of Patent: August 16, 2016Assignee: Anacor Pharmaceuticals, Inc.Inventor: Tsutomu Akama
-
Patent number: 9403850Abstract: Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.Type: GrantFiled: January 10, 2014Date of Patent: August 2, 2016Assignee: VENATORX PHARMACEUTICALS, INC.Inventors: Christopher J. Burns, Denis Daigle, Bin Liu, Daniel McGarry, Daniel C. Pevear, Robert E. Lee Trout, Randy W. Jackson
-
Patent number: 9388126Abstract: The present invention includes compounds useful in preventing, treating or ameliorating Sigma-related disorders or diseases. The compounds of the invention can modulate cellular protein homeostasis, which includes: translation initiation, folding, processing, transport, and degradation (including ubiquitin selective autophagy) of proteins. The present invention also includes methods of preventing, treating or ameliorating a Sigma-related disorder or disease in a subject in need thereof, the method comprising administering to the subject an effective amount of a Sigma-modulating compound. The present invention also includes methods of preventing, treating or ameliorating a Sigma-related disorder or disease in a subject in need thereof, the method comprising administering to the subject an effective amount of a Sigma-modulating compound, further comprising administering an effective amount of a compound that inhibits the ubiquitin proteasome system (UPS) and/or autophagic survival pathways.Type: GrantFiled: July 18, 2013Date of Patent: July 12, 2016Assignee: Drexel UniversityInventors: Felix J. Kim, Joseph M. Salvino
-
Patent number: 9346834Abstract: This invention provides, among other things, novel compounds useful for treating protozoal infections, pharmaceutical compositions containing such compounds, as well as combinations of these compounds with at least one additional therapeutically effective agent.Type: GrantFiled: October 19, 2010Date of Patent: May 24, 2016Assignee: Anacor Pharmaceuticals, Inc.Inventors: Huchen Zhou, Dazhong Ding, Daoan Sun, Yasheen Zhou, Yong-Kang Zhang, Jacob J. Plattner
-
Patent number: 9333212Abstract: A method of reducing damage to the ovary of a subject receiving chemotherapy is described. The method comprises the step of administering to the subject an amount of a proteasome inhibitor effective to reduce damage to the subject's ovary within a therapeutic time window prior to administration of a chemotherapeutic agent.Type: GrantFiled: February 26, 2014Date of Patent: May 10, 2016Assignee: Wisconsin Alumni Research FoundationInventors: Sana M. Salih, Elon Christiane Roti Roti
-
Patent number: 9296760Abstract: The present invention is related to novel compounds of formula (I) that may inhibit the activity of the FabI enzyme, and which are useful in the treatment of bacterial infections. It further relates to pharmaceutical compositions comprising these compounds, and chemical processes for preparing these compounds.Type: GrantFiled: August 9, 2013Date of Patent: March 29, 2016Assignee: Janssen Sciences Ireland UCInventors: Jerôme Emile Georges Guillemont, David Francis Alain Lançois, Magali Madeleine Simone Motte, Wendy Mia Albert Balemans, Anil Koul